Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). …

Somatic mutations within the kinase domain of the epidermal growth factor receptor (EGFR)
are present in approximately10% of non-small-cell lung cancer (NSCLC), with an increased …

Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the
epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to …

Gefitinib (Iressa, Astra Zeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets
the epidermal growth factor receptor (EGFR) and induces dramatic clinical responses in …

… Other abbreviations are as follows: (3AT) R : number of 3AT resistant colonies; (3AT) R *:
number of 3AT R clones that exhibited at least one additional two-hybrid phenotype [growth on …

Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that
respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific …

… The neutralizing HGF goat antibody was from R & D Systems, and the matched goat IgG
control antibody was from Sigma. All immunoblots were done with 1:1,000 antibody dilution, …

Kinase inhibitors constitute an important new class of cancer drugs, whose selective
efficacy is largely determined by underlying tumor cell genetics. We established a high-throughput …

RNA interference is a powerful tool for studying gene function, however, the reproducible
generation of RNAi transgenic mice remains a significant limitation. By combining optimized …

Mature adipocytes and myocytes are derived from a common mesenchymal precursor. While
IGF-1 promotes the differentiation of both cell types, the signaling pathways that specify the …